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Similar predictive value of bone turnover using first- and second- The term renal osteodystrophy refers to a spectrum of
generation immunometric PTH assays in pediatric patients treated bone diseases in patients with renal failure. The spectrum
with peritoneal dialysis.
ranges from high-turnover lesions arising predominantlyBackground. Accurate measurements of the concentration
from excess of parathyroid hormone (PTH) secretion toof parathyroid hormone (PTH) in serum or plasma are essential
for the proper assessment of renal osteodystrophy. The first- low-turnover lesions that are most often associated with
generation immunometric PTH assay (1st PTH-IMA) not only normal or reduced serum PTH levels [1]. Determinations
detects the intact hormone, but also additional PTH fragments
of PTH levels are used as surrogates for bone histology,truncated at the amino N-terminally truncated PTH-derived
which remains the most reliable method to establish thefragments [ntPTH(1-84)]. A second-generation immunometric
PTH assay (2nd PTH-IMA) recognizes only PTH(1-84) and diagnosis of renal osteodystrophy [2–4]. Accurate mea-
possibly PTH fragments that are truncated at the carboxyl- surements of the concentration of PTH in serum or plasma
terminus but not PTH(7-84). Whether estimates of the ratio
are therefore essential for the proper assessment of renalbetween PTH(1-84) and ntPTH(1-84) fragments are a better
osteodystrophy [5–9].predictor of bone turnover remains controversial.
Methods. Thirty-three patients aged 12.8 4.4 years treated The first clinically useful two-site immunometric PTH
with continuous cycling peritoneal dialysis (CCPD) for 13  9 assay (PTH-IMA) employed two antibodies directed
months underwent iliac crest bone biopsy. PTH levels were
against amino- and carboxyl-terminal epitopes, respec-measured by two newly developed first-generation and second-
tively, and was, therefore, predicted to measure only full-generation PTH-IMA. The ntPTH(1-84) fragments were calcu-
lated by subtracting PTH values determined using the 2nd length PTH(1-84) [10]. This first-generation immunomet-
PTH-IMA from values obtained using 1st PTH-IMA that de- ric PTH assay (1st PTH-IMA) proved to be a reasonablytects both PTH(1-84) and relatively large ntPTH(1-84).
reliable predictor of the different subtypes of renal osteo-Results. Determinations of PTH levels by both assays were
highly correlated (r  0.89, P  0.001). The relationships be- dystrophy, and it performed well in assessing the thera-
tween first-generation and second-generation PTH-IMA and peutic response to active vitamin D sterols in patients
bone formation were similar (r 0.67, P 0.0001 and r 0.64, with renal failure [5, 8, 9]. However, recent observationsP 0.0001, respectively). When patients were grouped according
highlight important shortcomings of this and other PTH-to the presence or absence of secondary hyperparathyroidism,
the ratio PTH(1-84) to ntPTH(1-84) did not differ between groups. IMAs [11, 12].
Conclusion. PTH concentrations determined by either the In particular, a series of studies by Brossard et al [11],
first- or the second-generation PTH-IMA were found to be better Lepage et al [12], Brossard et al [13], and Brossard, Yama-predictors of bone formation than the PTH(1-84) to ntPTH(1-84)
moto, and D’Amour [14], demonstrated that 1st PTH-fragments ratio.
IMAs detect not only the intact hormone, but also addi-
tional PTH fragments truncated at the amino terminusKey words: parathyroid hormone, immunometric PTH assay, perito-
neal dialysis. [ntPTH(1-84)]. Indeed, most of the detection antibodies,
which are usually directed against epitopes within the
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chromatography (HPLC) column with synthetic PTH(7-84) bone biopsy procedure; none of the patients received
prior intermittent calcitriol therapy. The study was ap-[12]. In contrast, a more recently developed second-gen-
eration immunometric PTH assay (2nd PTH-IMA) using proved by the UCLA Human Subject Protection Com-
mittee, and informed consent was obtained from all pa-a detection antibody raised against the first four amino
terminal amino acids of human PTH recognizes only tients and/or parents.
Patients were admitted to the UCLA General ClinicalPTH(1-84) and possibly PTH fragments that are truncated
at the carboxyl terminus but not PTH(7-84) [15–17]. Research Center and bone biopsies were obtained from
the anterior iliac crest using a modified Bordier trephineConsistent with this assessment human PTH(1-34), but
not human PTH(2-34) or other amino terminally truncated after double tetracycline as previously described [3]. Se-
rum samples for measurements of calcium, phosphorus,fragments of human PTH(1-34) cross-reacted with the
detection antibody [15–17]. First-generation PTH-IMAs, alkaline phosphatase, and PTH levels were obtained at
bone biopsy. Quantitative histomorphometry of bonethus, overestimate the true concentration of PTH(1-84)
in serum or plasma both in patients with ESRD and was done as previously described [3] and the terminology
established by the Nomenclature Committee of the Amer-those with normal renal function [14, 15, 17–19].
Recent in vitro and in vivo experimental data also ican Society of Bone and Mineral Research was used for
all the results [22]. Reference values from subjects withindicate that one or more amino terminally truncated
PTH(1-84) fragments antagonize the calcemic actions of normal renal function were obtained from iliac crest
bone biopsy done in 27 children between the ages of 2.5PTH(1-84) and diminish bone cell activity, and may,
thereby, modulate bone metabolism. These actions are and 17 years who had undergone elective orthopedic or
urologic surgery procedures. Normal bone formation ratepossibly mediated through a receptor distinct from the
type I PTH/PTHrP receptor [16, 20]. Such findings sug- ranged between 97 and 613 m2/mm2/day and such range
was utilized for the classification of patients into high, nor-gest that ntPTH(1-84) fragments may contribute to the
skeletal PTH resistance that occurs in patients with renal mal, or reduced rates of bone formation and turnover [3].
Serum calcium, phosphorus, and alkaline phosphatasefailure [16, 20]. It, therefore, appears plausible that an
levels were determined using a Technicon Autoanalyzerindependent assessment of PTH(1-84) and ntPTH(1-84)
II. Serum PTH determinations were performed by twofragments may have a better value for diagnosis of the
immunometric specific assays (Immutopics, San Clemente,different subtypes of renal osteodystrophy than each pa-
CA, USA), one that specifically detects only the biologi-rameter alone.
cally active full-length PTH(1-84) (2nd PTH-IMA) andIndeed, it has been suggested that estimates of the
another that detects with indistinguishable efficiency full-ratio between PTH(1-84) and ntPTH(1-84) fragments
length PTH(1-84) and the PTH(7-84) fragment (1st PTH-more accurately predicts bone remodeling and turnover
IMA) as has been previously described with a similar assayin patients with ESRD [18]. On the other hand, a more
[15]. Both assays use goat polyclonal antibodies purifiedrecent report failed to confirm such findings [21]. To
by affinity chromatography, which recognizes specificfurther examine the utility of 1st and 2nd PTH-IMAs as
and distant epitopes along the molecule. Most reagentspredictors of bone formation in ESRD, PTH measure-
used in both assays are identical (i.e., the same capturements were performed with two newly developed assays
antibody recognizing epitopes within the 39-84 region ofin pediatric patients treated with peritoneal dialysis.
the PTH molecule, identical standards and controls, and
identical buffer and incubation conditions). The differ-
METHODS ences between both assays are two distinct detection
A total of 33 patients, 13 females and 20 males, were antibodies (Fig. 1). For the 2nd PTH-IMA, the detection
entered into the study; the mean age at the time of bone antibody recognizes an initial epitope within the amino
biopsy was 12.8  4.4 years and they have been treated terminus (residues 1 to 3), and for the 1st PTH-IMA,
with CCPD for 13 9 months. All patients were treated the detection antibody recognizes an epitope within the
with peritoneal dialysis (Daniel, Baxter, Deerfield, IL, 13 to 34 region of the molecule. Thus, the assays measure
USA) with a dialysate calcium concentration of 2.5 different PTH fragment concentrations without influence
mEq/L and glucose concentration that was adjusted ac- by matrix, standard, or incubation procedures. Values for
cording to the needs for ultrafiltration. All patients were subjects with normal renal function range from 10 to 65
receiving calcium carbonate as phosphate-binding agent. pg/mL for the 1st PTH-IMA and 2 to 32 pg/mL for the
None of the patients were treated with steroids or cyclo- 2nd PTH-IMA.
sporine for at least 12 months prior to the biopsy and only
Evaluation of PTH fragment specificitytwo patients were previously treated with recombinant
human growth hormone, and therapy was discontinued 5 The specificity of the two immunometric PTH assays
and 11 months before the performance of the procedure. was determined by assessing cross-reactivity with increas-
ing concentrations of human (h) hPTH(7-84) (Bachem Cal-Therapy with calcitriol was held for 4 weeks before the
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RESULTS
Characterization of the two PTH assays
To assess the specificity of both immunometric assays,
each was characterized through in vitro competition ex-
periments using several synthetic PTH peptides. The 1st
PTH-IMA demonstrated equal cross-reactivity for both
hPTH(1-84) and hPTH(7-84), while the 2nd PTH-IMA
failed to detect hPTH(7-84) at concentrations as high as
20,000 pg/mL; (data not shown) these findings are consis-
Fig. 1. A description of the technical aspects of the first- and second-
tent with previous reports using a similar assay [15–17].generation immunometric parathyroid hormone assay (1st generation
and 2nd generation PTH-IMAs). Both assays employ capture antibodies The specificity of the two distinct detection antibodies,
that recognize epitopes within the 39 to 84 region of the PTH molecule. which are directed for both assays against an epitope
The differences between the assays are two distinct antibodies. In the
within the amino terminal portion of hPTH(1-84), was1st PTH-IMA, the detection antibody recognizes an epitope within
the13 to 34 region of the molecule. In contrast, for the 2nd PTH-IMA, further examined by incubating a constant concentration
the antibody recognizes an initial epitope within the amino terminus of hPTH(1-84) (545 pg/mL) with increasing amounts of(residues 1 to 3).
several different PTH fragments. In the 1st PTH-IMA,
specific binding of the detection antibody to hPTH(1-84)
was progressively and with similar efficacy reduced in
the presence of increasing concentrations of hPTH(1-34),ifornia, Inc., Torrance, CA, USA). Further characterization
hPTH(2-34), hPTH(3-34), hPTH(4-34), and hPTH(5-34)of both assays was obtained by coincubating hPTH(1-84)
(data not shown). In contrast, in the 2nd PTH-IMA,(545 pg/mL) with increasing concentrations of [Tyr34]
hPTH(1-34) revealed the highest efficacy to reduce bind-hPTH(1-34)amide (hPTH(1-34)), [Tyr34]hPTH(2-34)am-
ing of the detection antibody, while hPTH(2-34) andide (hPTH(2-34)), [Tyr-34]hPTH(3-34)amide (hPTH(3-34)),
hPTH(3-34) showed 50% and 4%, respectively, of[Tyr-34]hPTH(4-34) amide (hPTH(4-34)), and [Tyr34]hPTH
the potency of hPTH(1-34); hPTH(4-34) had a potency(5-34) amide (hPTH(5-34)) as described [15–17]. All pep-
of0.1%, and hPTH(5-34) completely failed to displacetides were synthesized and quantified by the Massachu-
the detection antibody.setts General Hospital Polymer Core Facility.
Comparison of 1st and 2nd PTH-IMAs in patientsStatistical analysis
treated with dialysis
All results are presented as the mean  one standard
Among the 33 bone biopsies with concurrent determi-deviation (SD). Patients were classified in two groups
nations of serum PTH levels by both assays, there wasaccording to the upper value for bone formation rate
evidence of increased bone formation rate, above the up-obtained in subjects with normal renal function after
per limit of normal, in 23 patients, lesion consistent withdouble tetracycline labeling [3]. PTH determinations ob-
secondary hyperparathyroidism; indices of bone forma-
tained with 1st and 2nd PTH-IMA as well as the
tion were within the normal range in seven patients, and
ntPTH(1-84) fragments and the ratio PTH(1-84) to values were below the lower limit of normal in three
ntPTH(1-84) fragments were compared between the two patients, lesion consistent with adynamic osteodystrophy
groups using Wilcoxon rank sum test. Under each group, as previously shown [3]. Patients were classified into two
the receiver operating curves (ROC) were generated for groups: (1) high bone turnover group, which includes all
the different tests (2nd PTH-IMA, 1st PTH-IMA, and the patients (N  23) with bone formation rates above the
ratio). The ntPTH(1-84) fragments were calculated by upper limit of normal from our laboratory [24]; and (2)
subtracting PTH values determined using the 2nd PTH- patients with normal/reduced bone turnover group (N 
IMA, which detects PTH(1-84) exclusively, from values 10), because these patients do not require vitamin D ther-
obtained using 1st PTH-IMA that detects both PTH(1- apy, and due to the small sample size of patients with
84) and ntPTH(1-84). The PTH(1-84)/ ntPTH(1-84) frag- adynamic bone. The mean age of the patients were 13.3
ments ratio was calculated as previously described [18]. 3.6 years and 11.7  5.8 years in the high and normal/
The areas under the ROC curves and their standard low turnover groups, respectively (NS), (Table 1) and
errors were obtained and comparisons were carried out the mean duration of treatment with peritoneal dialysis
as previously described [23]. For given cut off points, did not differ between the two groups. The mean values
sensitivity, specificity, number of true positive, true nega- for calcium, phosphorus, alkaline phosphatase activity,
tive, false positive, and false negative were calculated. and PTH determinations measured by 1st and 2nd PTH-
All statistical analyses were performed using software IMA in each of the two groups are shown in Table 1.
Serum calcium and phosphorus levels were similar in bothpackage SAS and two-sided significance level of 0.05.
Salusky et al: First- and second-generation immunometric PTH assays and bone turnover1804
Table 1. Patient characteristics and serum biochemical
determinations according to indices of bone turnover
High bone Normal/low
turnover bone turnover
(N  23) (N  10)
Bone formation ratea lm2/mm2/day 1314622 243208
Age years 13.33.6 11.75.8
Dialysis months 1310 129
Serum calcium mg/dL 8.60.9 8.41.0
Serum phosphorus mg/dL 6.71.5 6.10.9
Serum total alkaline phosphatase IU/L 469278 264137b
Serum 1st PTH-IMA pg/mL 893412 350325c
Serum 2nd PTH-IMA pg/mL 455256 150147c
NtPTH(1-84) fragments pg/mL 438212 200218c
Ratio PTH(1-84)/ntPTH(1-84)
fragments 1.110.57 1.071.27
Values are presented as meanSD. aRange of normal bone formation, 98 to
613m2/mm2/day; bP 0.02; cP 0.002 refer to differences between both groups,
respectively.
Fig. 3. Relationship between bone formation rate and parathyroid hor-
mone (PTH) levels determined by first-generation immunometric para-
thyroid hormone assay (1st PTH-IMA) (A ) and second generation
immunometric parathyroid hormone assay (2nd PTH-IMA) (B ).
Fig. 2. Relationship between serum parathyroid hormone (PTH) lev- bone formation rate are shown in Figure 3. The coeffi-
els determined by the first- and second-generation immunometric para-
cients of correlation were 0.67 and 0.64, P  0.00001thyroid hormone assay (1st PTH-IMA and 2nd PTH-IMA).
and P  0.00001, respectively, for these two assays. A
lower degree of correlation was found between bone
formation rate and serum total alkaline phosphatase ac-groups. In contrast, as expected, serum total alkaline phos-
tivity (r  0.38, P 0.03). On the other hand, the coeffi-phatase activity was higher in patients with elevated bone
cient of correlation between PTH(1-84)/ntPTH(1-84)turnover. Similarly serum PTH concentrations determined
fragment ratio and bone formation was 0.30 (not signifi-by 1st and 2nd PTH-IMA were higher in patients with
cant) (Fig. 4). Serum calcium levels and phosphorus lev-high turnover osteodystrophy, 893 412 pg/mL and 455
els did not correlate with bone formation rate.256 pg/mL, respectively, versus those with normal/ady-
To determine how accurately values of PTH obtainednamic lesion, 350  325 pg/mL and 150  147 pg/mL,
with either assay can differentiate between high and nor-respectively (Table 1).
mal/low osteodystrophy, receiver operating curves (ROCs)Overall, PTH levels obtained with 1st PTH-IMA were
were constructed. For the detection of high bone forma-on average 40% to 50% higher than those from the 2nd
tion a value greater than 613 mm2/mm2/day was utilizedPTH-IMA, which is similar to previously reported data
because it corresponds to the upper limit of normal of[15, 16, 18, 19, 21]. Determinations of PTH levels by 1st
tetracycline-based measurements of bone formation rateand 2nd PTH-IMA were highly correlated (r  0.89,
in individuals with normal renal function in our labora-P  0.0001) (Fig. 2). Furthermore, the concentration
tory (Fig. 5) [3]. The areas under the curve for the 1stof ntPTH(1-84) fragments was higher in patients with
and 2nd PTH-IMA were 0.866 and 0.870, respectivelyelevated bone formation rates than in those with normal
(not significant). In contrast, the area under the curveor reduced indices of bone turnover (Table 1), and the
ratio of PTH(1-84) over ntPTH(1-84) fragments did not for the PTH(1-84)/ntPTH(1-84) ratio was 0.694 and such
value is significantly lower than that obtained with 2nddiffer between the two groups (Table 1).
The relationships between 1st and 2nd PTH-IMA and PTH-IMA, P 0.01 and 1st PTH-IMA, P 0.05 (Fig. 6).
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Fig. 4. Relationship between bone formation rate and the ratio of
parathyroid hormone [PTH(1-84)]/[N terminally truncated (ntPTH(1-
84)] fragments. Fig. 6. Areas under the curve of the receiving operating curves (ROC)
for first- and second-generation immunometric parathyroid hormone
assay (1st PTH-IMA and 2nd PTH-IMA) and the ratio PTH(1-84)/[N
terminally truncated (ntPTH(1-84)] fragments. *P 0.05 and P 0.01,
refers to 1st PTH-IMA and 2nd PTH-IMA, respectively, versus the
ratio PTH(1-84)/ntPTH(1-84) fragments.
tions. These findings are consistent with previous obser-
vations and indicate that 1st PTH-IMA may overestimate
parathyroid gland function [15–19, 21]. On the other hand,
PTH concentrations were highly correlated and values
with both assays showed indistinguishable correlation with
indices of bone formation, as previously reported with
different 1st and 2nd PTH-IMAs [18, 21]. When patients
were grouped according to the presence or absence of
bone biopsy findings consistent with secondary hyper-
parathyroidism, serum PTH concentrations differed be-
tween both groups, as expected. PTH levels were consis-Fig. 5. Receiving operating curves (ROC) for the detection of bone
tently higher in the group with high bone turnover lesionsturnover with the first- and second-generation immunometric parathy-
roid hormone assay [1st PTH-IMA (dotted line) and 2nd PTH-IMA than in those with normal/adynamic osteodystrophy as
(broken line)] and the ratio PTH(1-84)/[N terminally truncated determined by both assays [18, 21]. Similar to PTH(1-84),(ntPTH(1-84)] fragments (solid line).
the ntPTH(1-84) fragments concentrations were higher
in patients with high rates of bone turnover than in those
with normal or reduced rates of bone formation as pre-
DISCUSSION viously shown [18, 21]. However, in contrast to a previous
study [18], the ratio PTH(1-84)/ntPTH(1-84) fragmentsThe results indicate that the 2nd PTH-IMA used in
did not differ between both groups. Furthermore, PTHthe current study detects only PTH(1-84), while the 1st
concentrations determined by either the 1st or the 2ndPTH-IMA cross-reacts equivalently with hPTH(7-84) and
PTH-IMA were found to be better predictors of bonehPTH(1-84) as has been previously shown for similar assays
formation than the ratio PTH(1-84)/ntPTH(1-84) frag-[15–17]. Furthermore, high concentrations of synthetic
ments, consistent with data recently reported by CoenhPTH(1-34) and to a lesser extent hPTH(2-34), hPTH(3-34),
et al [21] in adult patients treated with hemodialysis.hPTH(4-34), and hPTH(5-34) interfered with hPTH(1-
The ratio PTH(1-84)/ntPTH(1-84) fragments was pre-84) binding to the labeled detection antibody in the 2nd
viously reported to be a superior predictor of bone turn-PTH-IMA. In contrast, hPTH(3-34), hPTH(4-34), or
over when compared to PTH values determined by twohPTH(5-34) interacted poorly with this detection anti-
different IRMA assays and other biochemical markersbody suggesting that the first and second amino terminal
in adult patients treated with maintenance hemodialysisresidue of full-length PTH(1-84) are particularly impor-
[18]. These earlier results, therefore, differ not only fromtant for antibody recognition. Serum PTH determina-
those observed in the current study; but also from an-tions with the 1st PTH-IMA have been consistently
other study carried out in adult patients treated withhigher when compared to those obtained with the 2nd
PTH-IMA over a wide range of serum PTH concentra- hemodialysis [21]. Although different PTH assays were
Salusky et al: First- and second-generation immunometric PTH assays and bone turnover1806
utilized in the current study, in vitro characterization of tween 65 to 450 pg/mL, determined with 1st PTH-IMA
were poor predictors of bone turnover in patients under-these new assays did not differ significantly from those
previously described [15–17]. In fact, the use of different going maintenance dialysis. These differences compared
to those obtained in previous studies may be related toassays leading to the same conclusions makes it unlikely
that differences between PTH assays are responsible for selection bias, geographic differences, inclusion of pa-
tients treated with different dialytic modalities, and pre-the discrepant findings observed in the study by Monier-
Faugere et al [18]. Moreover, the criteria utilized for the vious vitamin D treatment, as well as the use of different
types of phosphate binders.grouping of patients according to indices of bone for-
mation differed between both studies. Indeed, Monier- On the other hand, discrepancies between serum PTH
levels as assessed by 1st PTH-IMA and indices of boneFaugere et al [18] included patients with normal bone
formation rate within the “high turnover” group, while formation have been described during intermittent calci-
triol therapy in pediatric patients treated with peritonealsuch patients were grouped in the current study with
those patients with adynamic osteodystrophy. Such crite- dialysis [25, 32]. Similar findings have been reported by
Andress et al [33], after treatment with intravenous cal-rion was used because of the different need for therapy
with vitamin D in these subtypes of renal bone diseases citriol in adult patients undergoing hemodialysis. The dis-
parity between the histologic and biochemical findings[24, 25]. Yet, even when ROC analysis was performed
according to the criterion established by Monier-Faugere highlights the potential limitation of single PTH determi-
nations to predict the skeletal manifestations of renal os-et al [18], the conclusions remained the same despite the
small number of patients with adynamic bone and are teodystrophy. Diurnal variations in serum ionized calcium,
as well as short-term variations in serum PTH levels duefurthermore consistent with the observations reported
by Coen et al [21]. to pulsatile PTH secretion could account for these findings
[34]. Another potential factor may be a direct inhibitoryDifferences in bone remodeling between adult and
pediatric patients may have played a role, but values of effect of calcitriol on differentiated osteoblastic function
not mediated through PTH [25, 32]. An alternative expla-bone formation rates were quite similar between prepu-
bertal, adolescents, and adult subjects with normal renal nation may be due to the overestimation of PTH levels
by 1st PTH-IMAs because of cross-reactivity with ntPTHand parathyroid gland function in our laboratory [25].
Moreover, the threshold of PTH levels as predictors (1-84) fragments [14–16, 18]. Although the precise struc-
ture of these putative large carboxyl-terminal PTH frag-of bone turnover was comparable between adult and
pediatric patients treated with dialysis using the 1st PTH- ments has yet to be identified, some of these fragments
exhibit chromatographic similarities to those of PTH(7-84)IMA [5–9]. In addition, diabetes was present in 40% of
the patients with low bone turnover in the study by [12] and may contribute to the discrepancy between se-
rum PTH levels and indices of bone formation duringMonier-Faugere et al [18], and it has been shown that
those patients have less biochemical evidence of second- intermittent calcitriol therapy [25, 32, 33, 35].
Indeed, recent studies have provided evidence thatary hyperparathyroidism than patients with other etiolo-
gies of ESRD [27, 28]. Insulin deficiency or tissue resis- such circulating fragments of truncated PTH may have
physiologic effects on bone metabolism. For example,tance to the actions of insulin may contribute to
reductions in osteoblastic activity [29]. It is interesting synthetic PTH(7-84) has been shown to have hypocalce-
mic properties when tested in vivo in parathyroidecto-to note, however, that diabetes was present only in 14%
of the patients reported by Coen et al [21] and in none mized rats fed a low calcium diet [16, 20]. In this bioassay
system, removal of the parathyroid glands leads to aof the patients in the current study. Finally, the tech-
niques for determination of bone turnover were different rapid decrease in serum calcium levels unless PTH(1-34)
or PTH(1-84) are given parenterally, and PTH(7-84) an-between studies. Ballant et al, however, demonstrated
that bone remodeling rates were comparable with both tagonized these calcemic activities of PTH molecules
with an intact amino terminus. Furthermore, whentechniques in the context of renal osteodystrophy and the
superiority of activation frequency was more conceptual PTH(1-84) was given simultaneously with PTH(7-84),
the PTH fragment decreased the phosphaturic effect ofthan practical [30].
Over the last decade, the 1st PTH-IMA was shown to the intact hormone by 50% [16]. Antagonistic effects of
PTH(7-84), thus, occurred not only at the level of bonebe a good predictor of the different subtypes of renal
bone diseases in children and adults treated with dialysis but also the kidney [16]. In addition, Nguyen-Yamamoto
et al [20, 35] have shown that PTH(7-84) with or without[5–9]. In such cross-sectional studies, patients at the time
of bone biopsy were treated with either daily calcitriol a mixture of other carboxyl terminal PTH fragments inhib-
ited the calcemic effect of PTH(1-34), indicating that thesetherapy or were not given vitamin D metabolites at all,
and calcium containing phosphate-binding agents were actions are not mediated through the PTH/PTHrP recep-
tor, but instead involve a receptor that interacts only withthe main phosphate-binding agents [5, 6, 8, 9]. Only the
study by Qi et al [31], documented that PTH levels be- the carboxyl terminal portion of PTH. Furthermore, Di-
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vieti et al [36] demonstrated that PTH(7-84), at concen- do not yet support the claim that 2nd PTH-IMAs provide
an advantage over 1st PTH-IMAs for the diagnosis oftrations that are likely to occur in renal failure, exerts a
direct antiresorptive effect on bone that it is not medi- the different subtypes of renal bone diseases [18]. In
summary, further studies are needed to establish theated through the PTH/PTHrP receptor, but probably
through a receptor specific for carboxyl-terminal frag- value of the new generation of PTH assays for assessing
ments of PTH, as mentioned above. Serum calcium levels bone disease in renal failure, during therapy with vitamin
may also act as regulators of the relative amounts of circu- D, and to address the need for higher PTH levels deter-
lating PTH(1-84) and ntPTH(1-84) fragments [37, 38]. mined by either assay for preventing the development
Indeed, it has been demonstrated that serum calcium of adynamic osteodystrophy and its consequences [26].
concentrations correlated with the percentage of these
PTH-derived fragments [38]. Thus, there is a growing ACKNOWLEDGMENTS
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